LY450139, A Phase III Clincal Trial on the Progression of Alzheimer's Disease

Alzheimer's Reading Room: LY450139, A Phase III Clincal Trial on the Progression of Alzheimer's Disease: "LY450139 is being tested to see if it can slow the progression associated with Alzheimer's disease by inhibiting gamma-secretase, an enzyme that can create a sticky protein called amyloid beta. Slowing the rate of disease progression could preserve independent functioning and quality of life for Alzheimer's patients in the milder stages of the disease, potentially delaying the onset of the severe stages of the disease."